Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Petrylak, Daniel; de Wit, Ronald; Chi, Kim; Drakaki, Alexandra; Sternberg, Cora; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed; Flechon, Aude; Bamias, Aristotelis; Yu, Evan; van der Heijden, Michiel; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Geczi, Lajos; Ou, Yen-Chuan; COŞKUN, HASAN; Su, Wen-Pin; Hegemann, Miriam; Percent, Ivor; Lee, Jae-Lyun; Tucci, Marcello; Semenov, Andrey; Laestadius, Fredrik; Peer, Avivit; Tortora, Giampaolo; Safina, Sufia; Garcia del Muro, Xavier; Rodriguez-Vida, Alejo; ÇİÇİN, İRFAN; HARPUTLUOĞLU, HAKAN; Widau, Ryan; Liepa, Astra; Walgren, Richard; Hamid, Oday; Zimmermann, Annamaria; Bell-McGuinn, Katherine; Powles, Thomas

doi:10.1016/s0140-6736(17)32365-6

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., ...Daha Fazla

LANCET, cilt.390, sa.10109, ss.2266-2277, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 390 Sayı: 10109
Basım Tarihi: 2017
Doi Numarası: 10.1016/s0140-6736(17)32365-6
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2266-2277
İnönü Üniversitesi Adresli: Evet

Özet

Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population.